Cannabidiol in treatment of refractory epileptic spasms: An open-label study
Herlopian A, Hess EJ, Barnett J, Geffrey AL, Pollack SF, Skirvin L, Bruno P, Sourbron J, Thiele EA. Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy & Behavior 2020, 106: 106988. PMID: 32169600, DOI: 10.1016/j.yebeh.2020.106988.Peer-Reviewed Original ResearchConceptsRefractory epileptic spasmsEpileptic spasmsResponder rateAdjunctive therapyCBD treatmentInvestigational new drug trialsOpen-label studyMonths of treatmentSafe adjunctive therapyNew drug trialsInstitutional review boardSubjective reportsBaseline medicationsCBD initiationElectrographic findingsHypsarrhythmia patternClinical responseSeizure frequencyAdverse eventsClinical efficacyElectrographic changesSubjective improvementTarget dosageDrug trialsInitial dosage